
BASEL, 09-Jun-2017 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that updates were presented on the ongoing clinical phase 1/2a program with its anticancer drug candidate BAL101553, a novel tumor checkpoint controller, at the American Society of Clinical Oncology … Read the full press release